NDLI: The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis.

Please wait, while we are loading the content...

Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease.

Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma.

Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.

A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.

Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy.

Prescription patterns of antidepressants: findings from a US claims database.

Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.

Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects.

Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.

Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.

The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis.

Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides.

Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.

Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China.

Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.

Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis.

Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study).

Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia.

Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention.

Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2.

Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes.

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations.

Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.

Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.

Year: 2010 Volume: 26 Issue: 5

Year: 2010 Volume: 26 Issue: 4

Year: 2010 Volume: 26 Issue: 3

Year: 2010 Volume: 26 Issue: Supplementary 3

Year: 2010 Volume: 26 Issue: 2

Year: 2010 Volume: 26 Issue: Supplementary 2

Year: 2010 Volume: 26 Issue: 1

Year: 2010 Volume: 26 Issue: Supplementary 1

Year: 2009 Volume: 25

Year: 2008 Volume: 24

Year: 2007 Volume: 23

Year: 2006 Volume: 22

Year: 1983 Volume: 8

The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Sullivan, Patrick W. Navaratnam, Prakash Lorber, Richard Shekar, Tulin
Spatial Coverage	France
Description	Country affiliation: United States Author Affiliation: Sullivan PW ( Department of Pharmacy Practice, Regis University, School of Pharmacy, Denver, CO 80221, USA. psulliva@regis.edu)
Abstract	OBJECTIVES: A new classification of persistent allergic rhinitis (PER) has been developed by the ARIA working group. Although the burden of AR is significant, treatment itself is also costly. It is unclear if treatment based on the new definition of PER is cost-effective. METHODS: The current study simulated the cost-effectiveness of desloratadine compared to placebo in the treatment of PER from the French societal perspective. Decision analysis was used to model the costs, effectiveness and cost-effectiveness over 12 months. Costs included medical expenditures (physician visits and prescription drugs) attributable to PER and related comorbidities and lost productivity due to absenteeism and presenteeism. Prices, tariffs and national wages were estimated from French national sources. MEASURES OF EFFECTIVENESS INCLUDED: symptom-based visual analogue scale (VAS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Total 5 Symptoms Score (T5SS), categorical improvement in therapeutic response, interference with activities of daily living (ADL) and sleep outcomes. Mild or symptom-free days and 'responders' were also captured as outcomes. Univariate and second-order multivariate probabilistic sensitivity analyses were conducted. RESULTS: Treatment with desloratadine dominated placebo (cost less and resulted in greater effectiveness) for all measures of effectiveness. Of the individuals taking desloratadine 46.8% were classified as 'responders' vs. 34.8% for placebo (p = 0.0012). Individuals taking desloratadine experienced mild/no symptoms for 57.6% of study days vs. 36.5% for placebo (p = 0.002). The expected annual cost of treatment with desloratadine (1819 euro) was less than placebo (2618 euro). Lost productivity was the most significant contributor to total cost. Results of the 10,000 Monte Carlo simulations showed that treatment was cost-saving in 99.6% of simulations. CONCLUSIONS: Treatment of PER with desloratadine resulted in improved effectiveness and significant savings. While the cost of drug treatment is greater than that of no treatment, the downstream costs associated with not treating PER significantly outweigh the cost of treatment. Key limitations include the comparison of desloratadine to placebo and the sources of cost and effectiveness measures. Future studies should examine the cost-effectiveness of all available treatments for PER. In addition, many utilization, productivity and effectiveness measures were taken from clinical trials and may not accurately reflect 'real world' treatment patterns and outcomes.
File Format	HTM / HTML
ISSN	03007995
Issue Number	6
Volume Number	26
e-ISSN	14734877
Journal	Current Medical Research and Opinion
Language	English
Publisher	Taylor & Francis
Publisher Date	2010-06-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Medicine Histamine H1 Antagonists, Non-sedating Economics Loratadine Analogs & Derivatives Rhinitis, Allergic, Seasonal Drug Therapy Adolescent Cost-benefit Analysis Female France Administration & Dosage Pharmacology Therapeutic Use Humans Male Randomized Controlled Trials As Topic Questionnaires Young Adult Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Safety evaluation of desloratadine in allergic rhinitis.

A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis.

Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms.

Pharmacokinetic evaluation of levocetirizine.

Desloratadine inhibits human skin mast cell activation and histamine release.

Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.

Study of levocetirizine in seasonal allergic rhinitis.

The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms.

The effectiveness of modern antihistamines for treatment of allergic rhinitis - an IPD meta-analysis of 140,853 patients.

The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis.

Similar Documents

Safety evaluation of desloratadine in allergic rhinitis.

A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis.

Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms.

Pharmacokinetic evaluation of levocetirizine.

Desloratadine inhibits human skin mast cell activation and histamine release.

Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.

Study of levocetirizine in seasonal allergic rhinitis.

The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms.

The effectiveness of modern antihistamines for treatment of allergic rhinitis - an IPD meta-analysis of 140,853 patients.

The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis.